结构治疗

最新新闻

• 评级变动
  H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Cuts Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $101
  \u5e02\u573a\u8d44\u8baf · 2026/6/8
• 公司公告
  SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL SIGNS COOPERATION AGREEMENT WITH U.S.-BASED ABALONE BIO TO JOINTLY DEVELOP A NEW-GENERATION INNOVATIVE THERAPY FOR WEIGHT LOSS AND MUSCLE GAIN, FURTHER DEEPENING ITS LAYOUT IN THE GPCR TARGET FIELD
  HKEX · 2025/10/30
• 评级变动
  A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $111
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  William Blair Maintains Structure Therapeutics(GPCR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/8
• 评级变动
  Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $126
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/9/9
• CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $111
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
  TipRanks · 2026/9/9
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/8/10
• 评级变动
  Citi Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $97
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: EnGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/9/9
• 评级变动
  J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/9
• 评级变动
  A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $97 to $145
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/6/8
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Cabaletta Bio (CABA) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/6/8
• A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $125
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/8/8

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。